This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Tuesday, March 14 • 11:45 - 12:45
Learning from each other - sample logistics in non-small molecule environments Part 1

Sign up or log in to save this to your schedule and see who's attending!

Feedback form is now closed.

The challenges of chemical sample management are shared by several neighbouring disciplines in industry and academia. Whilst each discipline has it’s unique problems, the solutions are often founded on common principles that translate across the broader sample management community. In this session, scientists from a diverse array of sample management disciplines will share their distinct experiences, the challenges they’ve overcome in providing a high quality service to support scientific research and development, and highlight the key factors under consideration for future improvements

11.45 Carlo R. Largiadèr
Health-care integrated biobanking, an important resource for precision medicine

Biobanks are essential for biomedical research and, more specifically, for the discovery and development of novel diagnostic biomarkers in the context of personalized medicine. They represent a reservoir for future clinical studies, and thus, accelerate the development and validation of new biomarkers and therapies, while reducing the costs of clinical research. Despite recent methodological advances in “omics-“technologies, the discovery of new biomarkers has been largely prevented by uncontrolled variability in the quality among and within existing biospecimen collections. Therefore, state of the art technological biobank infrastructure that enables researchers to meet the quality requirements of liquid samples is an indispensable precondition for the use of future analytical technologies, such as mass spectrometry. The Inselpital (University Hospital Bern) has implemented for its Liquid Biobank Bern an infrastructure, whose major focus is on sample quality. All pre-analytical processes are fully standardized and  integrated into the clinical routine. Samples are being frozen only one hour after the blood draw with every step in the pre-analytical process being electronically monitored and documented. Such modern health-care integrated and automated biobanks provide an important resource of high quality samples for the application of modern omics-technologies in clinical research. In particular, the ability to document the quality of samples is an important precondition to identify and to account for potential sources of bias that have led to irreproducible published results during the “omics”-hype.

12.10 Alan Brown
Optimising Clinical Laboratory Sample Usage

Every year AstraZeneca clinical studies produce hundreds of thousands of samples. Each and every sample is precious and comes with consent to be used for a specific purpose and has a defined stability. These samples are destined for a huge range of testing from simple safety to complex whole genome sequencing or Bio-banking for future use. Samples are generated and received from investigator sites all over the globe. Once simple, the modern clinical trial is biomarker heavy and often requires complex, multi-step testing using an array of specialist laboratories.

Overseeing the 160 Billion AstraZeneca sample movements each year are the Clinical Sample Scientists. A small operational team working to assist in laboratory selection, operational suitability, clinical trial laboratory set up and conduct.  

In 2016 this team undertook a huge challenge to re-model the way it worked. I will walk you through some of the challenges we faced and how we overcame them. How do we ensure samples from all over the world are fit for purpose? How do we govern the complex vendor landscape? How do we deal with the variable and ever changing regulatory requirements? How did we enable a change that impacted so many important internal and external stakeholders?

12.35 Snapshot Presentation:  

Scott VanderWoude, Wagner Medizin- und Pharmatechnik 

avatar for Clive Green

Clive Green

Director, R&D, Discovery Sciences, AstraZeneca
Clive received undergraduate and postgraduate degrees in Chemistry from the University of Nottingham, UK. He then completed postdoctoral research at the University of Pennsylvania, USA, before returning to the UK in 2001 as a medicinal chemistry Team Leader with AstraZeneca. As a medicinal chemist, Clive delivered projects in the Oncology and Cardiovascular disease areas, spanning all phases of drug discovery research. In 2010, he took up the... Read More →

avatar for Alan Brown

Alan Brown

Associate Director, Clinical Sample Sciences, Astra Zeneca
I graduated with an honours degree in Applied Biology from Brunel University, London. I spent 4 years at Huntingdon Life Sciences working at the bench in an environmental metabolism laboratory using techniques in HPLC and LC-MS to profile the degradation of agricultural and pharmaceutical compound sin simulated environments. I moved to a position of Project Manager for the central laboratory operation of Huntingdon Life Sciences to begin my... Read More →
avatar for Carlo Largiadèr

Carlo Largiadèr

Head of Liquid Biobank Bern, Institute of Clinical Chemistry, Bern University Hospital, University of Bern
Carlo R. Largiadèr (CRL) is a molecular population geneticist. He is currently vice director of the University Institute of Clinical Chemistry (UKC) at the Inselspital and the academic head of the Liquid Biobank Bern (LBB). CRL also heads a research group in pharmacogenomics and drug metabolism at the UKC (http://www.ukc.insel.ch/de/ukc-forschung/pharmacogenomics-and-drug-metabolism/). His current research focuses on genetic and... Read More →

Tuesday March 14, 2017 11:45 - 12:45
Music Hall 1